PMID- 34017551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210523
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 13
IP  - 4
DP  - 2021
TI  - Effect of gamma globulin combined with creatine phosphate on viral myocarditis.
PG  - 3682-3688
AB  - OBJECTIVE: This study aimed to investigate the effect of gamma globulin (IVIG) 
      and creatine phosphate (CP) on viral myocarditis (VMC). METHODS: We enrolled 121 
      young patients with VMC who were admitted in our hospital from February 2017 to 
      September 2018, and divided them into two groups as follows: study group (62 
      patients, IVIG + CP + routine treatment), and control group (59 patients, 
      conventional treatment). Patient's baseline data, including gender, age, disease 
      course, etiology, cardiac function classification, and severity, were collected. 
      Ejection fraction (EF), fractional shortening (FS), and mitral ratio of peak 
      early to late diastolic filling velocity (E/A ratio) before and after treatment 
      were recorded. These changes include the lactate dehydrogenase, creatine kinase 
      (CK), aspartate aminotransferase, creatine kinase isoenzyme (CK-MB), and cardiac 
      troponin I (CTnI). Furthermore, the changes in immune factors such as CD3(+), 
      CD4(+), and CD8(+) before and after the treatment were determined. RESULTS: The 
      study group had a significantly higher response rate than the control group (P < 
      0.05). After treatment, the ejection fraction, fractional shortening, and mitral 
      ratio of peak early-to-late diastolic filling velocity were more significantly 
      improved in the study group than in the control group (P < 0.05). The 
      electrocardiogram (ECG) results of the study group were also significantly better 
      than those of the control group (P < 0.05). The levels of lactate dehydrogenase 
      (LDH), creatine kinase (CK), aspartate aminotransferase (AST), creatine kinase 
      isoenzyme (CK-MB), and cardiac troponin I (CTnI) in the study group were all 
      significantly better than those in the control group (P < 0.05). Symptom 
      recuperation, cardiac function recovery, and ECG and myocardial enzyme 
      normalization were significantly faster in the study group than those in the 
      control group (P < 0.05). The immune factor levels in the study group also 
      significantly improved compared with those before the treatment (P < 0.05). 
      Meanwhile, the adverse reactions in both groups showed no differences (P < 0.05). 
      CONCLUSION: IVIG combined with CP exhibited better clinical effects and 
      effectively boosted the immune system of patients with VMC.
CI  - AJTR Copyright (c) 2021.
FAU - Li, Jing-Hui
AU  - Li JH
AD  - Zhangzhou Zhengxing Hospital Zhangzhou, China.
FAU - Li, Ting-Ting
AU  - Li TT
AD  - The Third Hospital of Zhangzhou Zhangzhou, China.
FAU - Wu, Xing-Sen
AU  - Wu XS
AD  - Zhangzhou Zhengxing Hospital Zhangzhou, China.
FAU - Zeng, Ding-Lin
AU  - Zeng DL
AD  - Zhangzhou Zhengxing Hospital Zhangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210415
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC8129424
OTO - NOTNLM
OT  - Viral myocarditis
OT  - creatine phosphate
OT  - gamma globulin
COIS- None.
EDAT- 2021/05/22 06:00
MHDA- 2021/05/22 06:01
PMCR- 2021/04/15
CRDT- 2021/05/21 06:32
PHST- 2020/09/23 00:00 [received]
PHST- 2021/01/07 00:00 [accepted]
PHST- 2021/05/21 06:32 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/05/22 06:01 [medline]
PHST- 2021/04/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2021 Apr 15;13(4):3682-3688. eCollection 2021.